한글목차

주요 7개 시장에서 당뇨병성 황반부종 진단을 받은 유병자 수는 2024년 288만 8,125명에서 2034년까지 346만 3,149명으로 연평균 성장률(AGR) 1.99% 증가할 것으로 예측됩니다. 2034년 주요 7개 시장 중 미국이 101만 2,428명으로 가장 많은 당뇨병성 황반부종 진단을 받은 유병자 수를 기록할 것으로 예상되며, 일본은 12만 5,490명으로 가장 적을 것으로 전망됩니다. GlobalData의 역학자들은 당뇨병성 황반부종(DME) 진단을 받은 유병자 수의 변화는 예측 기간 동안 주요 7개 시장의 유병률 추이 변화와 각 시장의 인구통계학적 변화로 인한 것으로 보고 있습니다.

본 보고서는 주요 7개국(미국, 프랑스, 독일, 이탈리아, 스페인, 영국, 일본)의 당뇨병성 황반부종(DME)에 대해 조사 분석했으며, 위험요인과 동반질환, 과거 역학 동향, 유병자 수 예측 등의 정보를 제공합니다.

목차

표목차

그림목차

제1장 당뇨병성 황반부종 : 주요 요약

• 촉매
• 관련 보고서
• 향후 보고서

제2장 역학

• 질환 배경
• 위험인자와 병존질환
• 세계의 과거 동향
• 주요 7개 시장 예측 방법
• DME의 역학 예측(2024-2034년)
  • 당뇨병에서의 DME 유병자 수
  • 당뇨병에서의 DME 진단된 유병자 수 : 연령별
  • 당뇨병에서의 DME 진단된 유병자 수 : 성별
  • DME 진단된 유병자 수 : 병변 부위별
• 논의
  • 역학 예측 인사이트
  • 분석의 한계
  • 분석의 강점

제3장 부록

영문목차

Diabetic macular edema (DME) is a vision-threatening complication of diabetes that is a major cause of vision impairment in diabetic individuals and is characterized by fluid accumulation in the macula due to a breakdown of the blood retinal barrier (BRB) (Cheema and Cheema, 2024). DME manifests as retinal thickening caused by the accumulation of intraretinal fluid, primarily in the inner and outer plexiform layers. It can occur due to hyperpermeability of the retinal vasculature. DME can occur with any level of diabetic retinopathy (DR) (Musat et al., 2015). The pathogenesis of DME is multifactorial and complex, with the hyperglycemic state caused by diabetes inducing multiple pathologic abnormalities, which ultimately lead to the sight-threatening conditions of macular edema and proliferative, neovascular retinopathy (Miller and Fortun, 2019). The common signs and symptoms of DME include blurry vision or double vision, difficulty seeing colors, dark spots or scotomas, straight lines seen as bent or curved, difficulty seeing during a glare or bright light, and seeing the same object in different sizes when seen with only alternate eyes (Macular Society, 2025).

In the 7MM, the diagnosed prevalent cases of DME in diabetes are expected to increase from 2,888,125 cases in 2024 to 3,463,149 cases in 2034, at an annual growth rate (AGR) of 1.99%. In 2034, the US will have the highest number of diagnosed prevalent cases of DME in diabetes in the 7MM, with 1,012,428 cases, whereas Japan will have the fewest diagnosed prevalent cases of DME in diabetes with 125,490 cases. GlobalData epidemiologists attribute the change in the diagnosed prevalent cases of DME in diabetes to changing prevalence trends in the 7MM and the changes in population dynamics in each market over the forecast period.

Scope

• This report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for DME in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
• The report includes a 10-year epidemiology forecast for the diagnosed prevalent cases of DME in diabetes. The diagnosed prevalent cases of DME are segmented by sex and age (ages 20 years and older) in these markets.
• The diagnosed prevalent cases of DME are further segmented by involvement of the eye by center involving DME (ci-DME), and non-center involving (nci-DME). This epidemiology forecast for DME is supported by data obtained from peer-reviewed articles and population-based studies.
• The forecast methodology was kept consistent across the 7MM to allow for a meaningful comparison of the diagnosed prevalent cases of DME across these markets.

Table of Contents

Table of Contents

List of Tables

List of Figures

1 Diabetic Macular Edema: Executive Summary

• 1.1 Catalyst
• 1.2 Related reports
• 1.3 Upcoming reports

2 Epidemiology

• 2.1 Disease background
• 2.2 Risk factors and comorbidities
• 2.3 Global and historical trends
• 2.4 7MM forecast methodology
  • 2.4.1 Sources
  • 2.4.2 Forecast assumptions and methods
  • 2.4.3 Forecast assumptions and methods: diagnosed prevalent cases of DME in diabetes - 7MM
  • 2.4.4 Forecast assumptions and methods: diagnosed prevalent cases of DME by involvement of the eye
• 2.5 Epidemiological forecast for DME (2024-34)
  • 2.5.1 Diagnosed prevalent cases of DME in diabetes
  • 2.5.2 Age-specific diagnosed prevalent cases of DME in diabetes
  • 2.5.3 Sex-specific diagnosed prevalent cases of DME in diabetes
  • 2.5.4 Diagnosed prevalent cases of DME by involvement of the eye
• 2.6 Discussion
  • 2.6.1 Epidemiological forecast insight
  • 2.6.2 Limitations of the analysis
  • 2.6.3 Strengths of the analysis

3 Appendix

• 3.1 Bibliography
• 3.2 About the authors
  • 3.2.1 Epidemiologist
  • 3.2.2 Reviewers
  • 3.2.3 Vice President of Disease Intelligence and Epidemiology
  • 3.2.4 Global Head of Pharma Research, Analysis, and Competitive Intelligence
• About GlobalData